We have cured many mice, but none of that translated to humans
In Seattle, a scientist named Jeff Carroll carries within him the same genetic sentence that claimed his mother and grandmother — Huntington's disease, a slow and certain erasure of self. Rather than surrender to private grief, he has transformed that inheritance into purpose, helping to lead a $400 million international initiative called the Brain Health accelerator, announced this week, which unites researchers across the world to pursue treatments for Alzheimer's, Parkinson's, Huntington's, and other neurodegenerative diseases. It is a rare convergence of the personal and the scientific: a man racing toward a cure he may need before the race is won, betting that human tissue research can succeed where generations of animal models have failed.
- Carroll, 48, carries the Huntington's mutation and has already begun noticing early signs — making his scientific mission inseparable from his own survival.
- Decades of promising laboratory breakthroughs in mice and cell cultures have repeatedly failed to translate into human treatments, leaving patients and families without relief.
- The Brain Health accelerator shifts the field's methodology toward human brain tissue — including over 300 donated Huntington's brains at UBC — in a direct attempt to close the gap between lab and clinic.
- With $400 million from the Allen Institute, the Bezos family, Amazon Web Services, the NIH, and EverythingALS, the initiative has the scale to pursue Alzheimer's, Parkinson's, ALS, and Lewy body dementia simultaneously.
- Human trials are targeted for 2031, but researchers caution that regulatory approval can take 10 to 15 years and cost up to a billion dollars per treatment — hope must be tempered with realism.
- Carroll's own children were spared the gene through preimplantation genetic screening, yet he remains clear that this victory does nothing for those already carrying the mutation — including himself.
Jeff Carroll is 48 years old and knows he will one day develop Huntington's disease. His grandmother died from it. His mother died from it. He carries the same mutant gene, and there is no escaping that inheritance. Rather than retreating into private dread, he chose to channel his fear into science — reasoning, as he told a radio interviewer, that he might as well do something useful with all that anxiety.
This week, that decision bore fruit on a scale few researchers ever see. Carroll is helping to lead the Brain Health accelerator, an international consortium announced Tuesday with $400 million in backing — $200 million from the Allen Institute in Seattle, $100 million from the Bezos family office, and $100 million split among Amazon Web Services, the NIH, and EverythingALS. The initiative targets Alzheimer's, Parkinson's, Huntington's, Lewy body dementia, and ALS, with the hope that breakthroughs might also illuminate pathways for epilepsy, brain tumors, and developmental disorders.
What distinguishes this effort is its methodology. Scientists have cured Huntington's in rodents, Parkinson's in laboratory models, Alzheimer's in petri dishes — and none of it has translated to human patients. Carroll and his colleagues argue the field has been approaching the problem wrong. The accelerator pivots toward human brain tissue, including more than 300 donated brains housed at UBC's HD Biobank, in hopes that findings will be more directly convertible into real treatments.
Carroll's mentor, Dr. Michael Hayden, initially hesitated before bringing him into the lab — knowing the emotional weight of asking someone to chase a cure they might personally need. He ultimately decided Carroll had the resilience the work demanded, and he was right. Over the years, Carroll has participated in observational studies both as scientist and subject, his own body slowly becoming a case study in the disease he is trying to defeat.
Huntington's is relentless in what it takes. Carroll watched it hollow out his mother — eroding her ability to work, to speak, to control her emotions. Hayden described it plainly: it robs people of their humanity, casting a black cloud over entire family lines. Carroll did manage to break the cycle for his own children: in 2005, he and his wife used preimplantation genetic diagnosis, and their twins — the first successful commercial PGD births in British Columbia — were born free of the gene. But Carroll is clear-eyed that screening prevents inheritance; it does nothing for those already carrying the mutation.
The accelerator aims to begin human trials by 2031. Hayden cautions that regulatory approval typically takes 10 to 15 years and can cost up to a billion dollars per drug, urging careful hope over false promise. Carroll's framing is simpler: "We owe this generation our best work towards a cure." He is speaking about people like himself — people who know what is coming, and who have decided not to wait passively for it to arrive.
Jeff Carroll is 48 years old and knows with certainty that he will one day develop Huntington's disease. His grandmother died from it. His mother died from it. He carries the same mutant gene they carried, and there is no escape from that inheritance. He has already begun to notice signs—small tremors in his thinking, perhaps, the early whispers of what is coming. But he is not yet sick, not yet trapped in the slow erasure that claimed the women before him.
Instead of retreating into private dread, Carroll chose to build something. He is a scientist at the Allen Institute in Seattle, and he decided that if he was going to spend his life thinking about Huntington's disease anyway—if anxiety about his own future was going to be his constant companion—he might as well channel that fear into work that could matter. "I might as well do something useful with all this anxiety," he told a radio interviewer recently.
This week, that decision bore fruit on a scale that few individual researchers ever see. Carroll is now helping to lead the Brain Health accelerator, an international research consortium announced Tuesday with $400 million in backing. The money comes from multiple sources: $200 million from the Allen Institute itself, $100 million from the Bezos family office, and another $100 million split among Amazon Web Services, the National Institutes of Health, and EverythingALS. The initiative brings together researchers from around the world to study some of neurology's most intractable problems—Alzheimer's, Parkinson's, Huntington's, Lewy body dementia, and ALS—with the hope that breakthroughs in these areas could eventually illuminate pathways for epilepsy, brain tumors, and developmental neurological disorders.
What makes this effort different from decades of prior research is methodological. Scientists have spent generations studying brain disease in mice and cell cultures, and the results have been grim: they have cured Huntington's in rodents countless times, cured Parkinson's in laboratory models, cured Alzheimer's in petri dishes. None of it has translated to human patients. Carroll and his colleagues argue that the field has been approaching the problem wrong. The Brain Health accelerator is shifting focus toward human tissue—real brain samples from real patients—in hopes that findings will be more relevant and more quickly convertible into actual treatments. The HD Biobank at the University of British Columbia, which houses more than 300 donated brains from Huntington's patients, will be a crucial resource for this work.
Carroll's mentor, Dr. Michael Hayden, a pioneering Huntington's researcher at UBC, initially hesitated before bringing Carroll into his lab years ago. Hayden knew the emotional weight of what he was asking: What if the research failed? What if Carroll spent his career chasing a cure he would never find, all while watching his own disease approach? After talking it through, Hayden decided Carroll possessed the resilience and commitment the work demanded. He was right. Over the years, Carroll has participated in observational studies both as a scientist and as a living subject—a person whose body and mind are slowly becoming a case study in a disease he is trying to defeat.
Huntington's disease is relentless in what it takes. Carroll watched it hollow out his mother—eroding her ability to work, to control her emotions, to speak clearly. It attacks the very architecture of personhood. "Our brain is the seed of all of those things," Carroll said. Hayden described it more starkly: "It's a devastating disease, and it really robs you of your humanity. The cycle of destruction in families feels like a black cloud threatening to smother them."
There is one way Carroll has managed to break the cycle for his own children. In 2005, he and his wife participated in a trial of preimplantation genetic diagnosis—an IVF procedure that screens embryos for the Huntington's mutation before implantation. Their twins, born that year, were the first successful commercial PGD births in British Columbia. Neither inherited the gene. But Carroll is clear-eyed about the limits of this victory: genetic screening prevents future generations from inheriting the disease, but it does nothing for people like him, already carrying the mutation, or for the many neurodegenerative diseases that simply develop over time in people with no family history.
The Brain Health accelerator aims to have human trials underway by 2031. That is an ambitious timeline, though Hayden cautions that the path from identifying a treatment to winning regulatory approval typically takes 10 to 15 years and costs up to a billion dollars per drug. Still, he believes the effort is necessary. "We have to be very cautious about raising too much hope," Hayden said. "But we need to be hopeful that we can make insights that in the long run will identify new targets for treatment." Carroll's framing is simpler and more urgent: "We owe this generation our best work towards a cure." He is speaking about people like himself—people who know what is coming, and who have decided not to wait passively for it to arrive.
Citas Notables
I'll be thinking about it anyway. I might as well do something useful with all this anxiety.— Jeff Carroll
It's a devastating disease, and it really robs you of your humanity. The cycle of destruction in families feels like a black cloud threatening to smother them.— Dr. Michael Hayden, University of British Columbia
La Conversación del Hearth Otra perspectiva de la historia
Why did you decide to stay in this field when you could have walked away, chosen something else?
Because I was going to think about it anyway. The anxiety doesn't disappear if you ignore it. I figured I might as well make the anxiety productive, turn it into something that could help other people facing what I'm facing.
Your mentor hesitated before bringing you into the lab. What do you think changed his mind?
I think he realized that the emotional stakes, as complicated as they are, also mean I have a kind of clarity about what matters. I'm not studying this disease in the abstract. I'm studying it because I know what it does, because I've watched it destroy people I loved.
You've cured Huntington's in mice many times. Why hasn't any of that worked in humans?
We've been asking the wrong questions of the wrong systems. A mouse brain isn't a human brain. A cell in a dish isn't a living person. We need to study actual human tissue, actual human disease, if we want answers that will actually translate.
Your children don't carry the gene. Does that change how you think about your own future?
It changes everything and nothing. I'm grateful they won't face what I'm facing. But it doesn't cure me. It doesn't cure the people already living with these mutations. We owe this generation our best work.
What does it feel like to be both the scientist and the subject?
It's clarifying. I can't hide behind abstraction. I know exactly what's at stake because it's at stake for me. That focus—that urgency—it matters in this work.